TiumBio Begins Patient Dosing in Phase 2 Trial of Oral Immuno-Oncology Drug TU2218

TiumBio Begins Patient Dosing in Phase 2 Trial of Oral Immuno-Oncology Drug TU2218

Overview

TiumBio Co., Ltd., a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in its phase 2 clinical trial of TU2218.

About TU2218: an Oral Dual Inhibitor

  • TU2218 is a novel oral dual inhibitor targeting TGFR1 and VEGFR2. 
  • TGF-ß and VEGF pathways are known to suppress the activity of immune checkpoint inhibitors (ICIs), so TU2218 is expected to improve the efficacy of ICIs by blocking the two pathways.

The Trial

  • In phase 1a and 1b clinical trials, TiumBio evaluated the safety, pharmacokinetics, and pharmacodynamics of TU2218 as a monotherapy and in combination with Keytruda (pembrolizumab) in 41 patients with advanced solid tumours. 
  • These profiles were used to determine the dose levels for phase 2 trials. 
  • The phase 2a trial is designed to assess the safety and efficacy of TU2218 in combination with Keytruda in patients with head and neck squamous cell carcinoma (HNSCC), biliary tract cancer (BTC), and colorectal cancer (CRC).

Phase 2 Trial location

  • The phase 2 trial begins at Seoul National University Hospital and Asan Medical Center in South Korea, which is planned to expand to hospitals in the United States. 
  • The first dose was administered to an HNSCC patient.

HNSCC Tumours

  • HNSCC refers to malignant tumours that occur in the oral cavity, throat, larynx, or salivary glands. 
  • The standard treatment typically involves surgery and radiation therapy. 
  • According to Global Data, as of 2023, the number of HNSCC patients worldwide is estimated to be around 610,000, and it is expected to exceed 670,000 by 2030.

Statement from the CEO: TiumBio

  • HNSCC is a disease with a high unmet medical need, as the average survival rate for first-line treatments is known to be only about one year,"" said Hun-taek Kim, Ph.D., MBA, CEO of TiumBio. 
  • We have selected cancer types for the phase 2 clinical trial based on other trials that demonstrated strong anti-cancer effects from targeting TGF- ß or VEGF pathways. Our goal is to develop TU2218 as a first-line treatment for HNSCC,” he added.

In the phase 1b trial, among 10 patients with advanced solid tumours who received a 195mg daily dose (the determined dose for Phase 2) of TU2218 with Keytruda, three patients achieved partial response (PR) and five patients had stable disease (SD), yielding an 80% disease control rate (DCR).

About the Company: TiumBio

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!